Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian carcinoma prevalent in Asians. No clear therapeutic selection based on molecular profile has been implemented for this disease. Oncogenic PIK3CA mutation, which activates the PIK3CA/AKT/mTOR signaling pathway, is a promising druggable alteration in OCCC. Recent studies by our group and others have identified the ARID1A mutation as another alteration linked to therapeutic selection based on synthetic lethality: deleterious ARID1A mutations, resulting in ARID1A deficiency, make OCCC cells sensitive to drugs targeting poly (ADP-ribose) polymerase and EZH2, as well as to glutathione inhibitors. In addition, we recently obtained evidence that ARID1A-deficient OCCC could benefit from gemcitabine treatment. Precision medicine based on gene alteration profiling might improve the prognosis of OCCC patients.

中文翻译：

---

基于基因改变的卵巢透明细胞癌精密医学。

卵巢透明细胞癌（OCCC）是亚洲人中普遍存在的上皮性卵巢癌的组织学亚型。尚未针对该疾病实施基于分子谱的明确治疗选择。激活PIK3CA / AKT / mTOR信号通路的致癌PIK3CA突变是OCCC中有希望的可药物改变。我们小组和其他人最近的研究已将ARID1A突变确定为与基于合成杀伤力的治疗选择相关的另一种改变：有害的ARID1A突变导致ARID1A缺乏，使OCCC细胞对靶向聚ADP-核糖聚合酶和EZH2的药物敏感，以及谷胱甘肽抑制剂。此外，我们最近获得的证据表明，缺乏ARID1A的OCCC可以从吉西他滨治疗中受益。